This study investigated the relationship between clinicopathological factors, pCR, and relapse in HER2+ BC patients treated with NAT, incorporating chemotherapy, trastuzumab, and pertuzumab, in a real-world context, using an international cohort. Here, ERBB2 is linked to breast cancer.